Xu Jing, Li Jing-Quan, Chen Qi-Lei, Shestakova Elena A, Misyurin Vsevolod A, Pokrovsky Vadim S, Tchevkina Elena M, Chen Hu-Biao, Song Hang, Zhang Jian-Ye
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Department of Biochemistry and Molecular Biology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Front Pharmacol. 2022 Jun 13;13:920779. doi: 10.3389/fphar.2022.920779. eCollection 2022.
Cancer is a common and intractable disease that seriously affects quality of life of patients and imposes heavy economic burden on families and the entire society. Current medications and intervention strategies for cancer have respective shortcomings. In recent years, it has been increasingly spotlighted that chemokines and their receptors play vital roles in the pathophysiology of cancer. Chemokines are a class of structurally similar short-chain secreted proteins that initiate intracellular signaling pathways through the activation of corresponding G protein-coupled receptors and participate in physiological and pathological processes such as cell migration and proliferation. Studies have shown that chemokines and their receptors have close relationships with cancer epigenetic regulation, growth, progression, invasion, metastasis, and angiogenesis. Chemokines and their receptors may also serve as potential targets for cancer treatment. We herein summarize recent research progresses on anti-tumor effects and mechanisms of chemokines and their receptors, suggesting avenues for future studies. Perspectives for upcoming explorations, such as development of multi-targeted chemokine-based anti-tumor drugs, are also discussed in the present review.
癌症是一种常见且棘手的疾病,严重影响患者的生活质量,并给家庭和整个社会带来沉重的经济负担。目前用于癌症的药物和干预策略都有各自的缺点。近年来,趋化因子及其受体在癌症病理生理学中发挥重要作用这一点越来越受到关注。趋化因子是一类结构相似的短链分泌蛋白,它们通过激活相应的G蛋白偶联受体启动细胞内信号通路,并参与细胞迁移和增殖等生理和病理过程。研究表明,趋化因子及其受体与癌症表观遗传调控、生长、进展、侵袭、转移和血管生成密切相关。趋化因子及其受体也可能作为癌症治疗的潜在靶点。我们在此总结了趋化因子及其受体抗肿瘤作用和机制的最新研究进展,并提出了未来研究的方向。本综述还讨论了即将开展的探索的前景,例如开发基于趋化因子的多靶点抗肿瘤药物。